Skip to main content
. 2018 Aug 17;3:32. doi: 10.1038/s41541-018-0071-7

Fig. 2.

Fig. 2

Analysis of the purified final RH5.1 drug product. a Overview of RH5.1 protein vaccine cGMP production process. b SDS-PAGE and c western blot (under reducing conditions) of the final RH5.1 drug product produced to cGMP (G) run alongside the comparator engineering batch (E). The western blot used the anti-PfRH5 4BA7 mouse mAb. Within each panel, the gels derive from the same experiment and were processed in parallel. d HPLC-SEC analysis of the final RH5.1 drug product to assess aggregation. M molecular weight markers